UPDATED: Clear 'Yes' From Shareholders On Takeda/Shire Deal
Executive Summary
Dec. 5, 2018 was a big day in the timeline of Takeda's proposed acquisition of Shire, with shareholder votes being held at both companies. The deal passed the first of its final hurdles, easily receiving approval at an EGM of Takeda shareholders, followed by a similar positive vote of confidence from Shire investors.
You may also be interested in...
Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain
Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.
Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun
With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.